Previous 10 | Next 10 |
Data from randomized controlled clinical trial evaluating Horizon Therapeutics' ([[HZNP]] -2.4%) Krystexxa (pegloticase injection) concomitantly used with an immunomodulator, shows improved response rates as compared to Krystexxa monotherapy.19/22 (86.4%) of patients ...
-- Primary study endpoint demonstrates 86 percent response rate for patients receiving co-therapy of KRYSTEXXA and mycophenolate mofetil -- -- RECIPE RCT results will be detailed during an oral presentation on Nov. 7 at 5:20 p.m. ET as part of the American College of Rheumatol...
Horizon Therapeutics PLC (HZNP) Q3 2020 Earnings Conference Call November 02, 2020, 08:00 ET Company Participants Tina Ventura - SVP, IR Timothy Walbert - Chairman, President & CEO Elizabeth Thompson - Group Vice President, Clinical Development and External Search Paul Hoelscher - EVP &am...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2020 Q3 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2020 Q3 - Results - Earnings Call Presentation
Horizon Therapeutics (HZNP) Q3 results:Revenues: $636.4M (+89.7% Y/Y) vs consensus of $531.11M.Tepezza (teprotumumab-trbw) Q3 net sales of $286.9M.Orphan and Rheumatology Segment: Krystexxa: $108.5M (+9%); Ravicti: $64.6M (+8%); Procysbi: $43.1M (+7%); Actimmune: $28.3M (+2%); Buphenyl: ...
Horizon Therapeutics (HZNP): Q3 Non-GAAP EPS of $1.74 beats by $0.77; GAAP EPS of $1.31 beats by $1.13.Revenue of $636.4M (+89.7% Y/Y) beats by $105.29M.Non-GAAP gross margin of 86.7% vs. consensus 87.4%.Non-GAAP EBITDA of $329.8M vs. estimate of $224.9M.Press Release For further details se...
-- Record Third-Quarter 2020 Net Sales of $636.4 Million Increased 90 Percent; Third-Quarter 2020 GAAP Net Income of $292.8 Million; Adjusted EBITDA of $329.8 Million -- -- Quarterly Orphan Segment Net Sales Increased 131 Percent to $534.8 Million, Representing Nearly 85 Perce...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and chief scientific officer, reporting directly to Tim Walbert, chairman, president and chief executive officer. ...
[[AMCX]], [[BWXT]], [[CDW]], [[CLX]], [[CNA]], [[CWH]], [[DEA]], [[EL]], [[FE]], [[HLIO]], [[HSIC]], [[HZNP]], [[IAA]], [[INGR]], [[ITRI]], [[JLL]], [[LCII]], [[LDOS]], [[LITE]], [[LL]], [[MGP]], [[MPC]], [[MPLX]], [[MSGN]], [[NI]], [[NNN]], [[NSP]], [[TEN]], [[USFD]], [[WING]], [[WM]], [[XEN...
Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q3 earnings results on Monday, November 2nd, before market open.The consensus EPS Estimate is $0.97 (+51.6% Y/Y) and the consensus Revenue Estimate is $531.11M (+58.3% Y/Y).Over the last 2 years, HZNP has beaten EPS estimates 100% of...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...